Podium to Practice: ESMO® 2025 – GU: PR.21

Podium to Practice: ESMO® 2025 – GU: PR.21

Podium to Practice: ESMO® 2025
Explore more from your favourite experts – click their name to access their entire library of content.
Icon Chair Speaker

Chair

Dr. Christian Kollmannsberger

Icon Chair Speaker

Speakers

Dr. Sebastien Hotte

Dr. Maria Jiang

Studies / Trials Discussed

LBA89 – A randomized phase 2 study of 177Lu-PSMA-617 vs docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC) and PSMA-positive disease: Canadian Cancer Trials Group (CCTG) study PR.21

Studies/trials discussed:

LBA89 – A randomized phase 2 study of 177Lu-PSMA-617 vs docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC) and PSMA-positive disease: Canadian Cancer Trials Group (CCTG) study PR.21
Tagged